Fundraising Fox
🦊/People
Sign in

Scott Biller

Investor

Executive Venture Partner at GV (Google Ventures) · Director at Remix Therapeutics

Boston, Massachusetts

Writes $250K – $50M checks · typically $25M

Find your path to Scott

252 people in our graph share verified history with Scott — schools, employers, funds. One of them is your warm intro.

David SchenkeinunlockedScott: together at Agios Pharmaceuticals (2010–2023)
×11Scott: together at GV (Google Ventures)

About

Dr. Scott Biller is an Executive Venture Partner at GV with a deep R&D background, having served as Chief Scientific Officer of Agios Pharmaceuticals and held leadership roles at Novartis and Bristol-Myers Squibb. He advises and sits on the boards of several biotech companies including Foghorn, Remix, Rome, and OMass Therapeutics.

Invests in

BiotechMedical Devices

Director at Remix Therapeutics

Intro paths

→

In turn, Scott can intro founders to Remix Therapeutics's investors below.

Remix Therapeutics's investors · 5

ARCH Venture PartnersChicago · $50K – $250M checks · since 2023Atlas VentureCambridge · $500K – $1M checks · since 2024Decheng CapitalMenlo Park · since 2023Foresite CapitalWest Hollywood · since 2024The Column GroupSan Francisco · $30M checks · since 2024

Co-founders at Remix Therapeutics

PS
Peter Smith, PhDCo-Founder, President and Chief Executive Officer
PS
Peter SmithCo-Founder, President and Chief Executive Officer

Experience

  1. OMass TherapeuticsBoard Membercurrent2022 — present
  2. GVExecutive Venture Partnercurrent2021 — presentCambridge, Massachusetts, United States
  3. ROME TherapeuticsBoard Membercurrent2021 — present
  4. Gate BioscienceBoard Observercurrent2021 — present
  5. Remix TherapeuticsBoard Membercurrent2020 — present
  6. Foghorn Therapeutics, IncBoard Membercurrent2020 — present
  7. VividionScientific Advisory Board member2019 — 2024
  8. Agios PharmaceuticalsScientific Advisory Board member2021 — 2023
  9. Agios PharmaceuticalsStrategic Advisor2020 — 2021
  10. Agios PharmaceuticalsChief Scientific Officer2010 — 2019
  11. Denali TherapeuticsScientific Advisory Board member2015 — 2023
  12. Novartis Institutes for BioMedical ResearchVice President, Global Discovery Chemistry2003 — 2010
  13. Bristol-Myers SquibbVice President, Pharmaceutical Candidate Optimization2001 — 2003
  14. Bristol Myers SquibbDirector, Executive Director, Discovery Chemistry1995 — 2001
  15. MITStudent1972 — 1976

Skills & more

Drug DiscoveryMedicinal Chemistry56Pharmaceutical Industry82Drug Design40Organic Chemistry52Oncology34ChemistryDrug DevelopmentLead Change24Lifesciences16Pharmacology27Cancer12
+7 moreBiochemistryADMEAssay DevelopmentCRONeuroscienceOrganic SynthesisLife Sciences

From Scott's professional profile.

Investments

Board seats

Foghorn TherapeuticsOMASS TherapeuticsRemix TherapeuticsRome Therapeutics

Investor

Gate BioscienceOMass Therapeutics

Sources: the firm's website · curated public sources.

Colleagues at GV (Google Ventures)

Andrew Wheeler
General Partner at GV (Google Ventures)
Anika Gupta
Investor at GV (Google Ventures)
Anika Gupta Vatsa
Principal at GV (Google Ventures)
Anthony Philippakis
Investor at GV (Google Ventures)
Ben Robbins
Investor at GV (Google Ventures)
Braden Kowitz
Investor at GV (Google Ventures)
Bradley Horowitz
Investor at Wisdom Ventures
Brendan Bulik-Sullivan
Investor at GV (Google Ventures)

Frequently asked questions

Who is Scott Biller?
Dr. Scott Biller is an Executive Venture Partner at GV with a deep R&D background, having served as Chief Scientific Officer of Agios Pharmaceuticals and held leadership roles at Novartis and Bristol-Myers Squibb. He advises and sits on the boards of several biotech companies including Foghorn, Remix, Rome, and OMass Therapeutics.
Where does Scott Biller work?
Scott Biller is Executive Venture Partner at GV (Google Ventures).
What does Scott Biller invest in?
Scott Biller invests in Biotech, Medical Devices.
What check size does Scott Biller write?
Scott Biller typically writes checks of $250K – $50M.
What boards does Scott Biller sit on?
Scott Biller holds tracked board seats at Foghorn Therapeutics, OMASS Therapeutics, Remix Therapeutics, Rome Therapeutics.
What companies has Scott Biller invested in?
Investments tracked here include Gate Bioscience, OMass Therapeutics.
Where did Scott Biller go to school?
Scott Biller studied at Massachusetts Institute of Technology (BS, Chemistry); Columbia University (Postdoc, Organic Chemistry); Caltech (PhD, Organic Chemistry).

Same school

Shared employers